Gboxin
目录号 : GC33234Gboxin是癌细胞中氧化磷酸化(OXPHOS)的抑制剂,能够靶向抑制胶质母细胞瘤(GBM)。
Cas No.:2101315-36-8
Sample solution is provided at 25 µL, 10mM.
Gboxin is an inhibitor of oxidative phosphorylation (OXPHOS) in cancer cells and can be targeted to inhibit glioblastoma (GBM)[1]. Gboxin is a trisubstituted benzimidazolium compound containing a positive charge that can specifically inhibit the growth of multiple cancer cell lines[2]. Gboxin specifically inhibits GBM growth by inhibiting the activity of F0F1 ATPase complex V, but its anti-GBM effect is severely limited by poor blood circulation, blood-brain barrier (BBB) and non-specific GBM tissue/cell uptake[3]. Gboxin can inhibit the expression of thioredoxin-interacting protein, which is a regulator of glucose uptake and consumption and a target of oxidative phosphorylation OXPHOS[4].
In vitro, Gboxin (0-15μM) treatment of HTS cells, primary MEF cells and astrocytes for 96h significantly inhibited the growth of HTS cells, but did not inhibit the growth of primary MEFs and astrocytes, and reduced the mitochondrial membrane potential in HTS cells[5].
References:
[1] Zou Y, Sun Y, Wang Y, et al. Cancer cell-mitochondria hybrid membrane coated Gboxin loaded nanomedicines for glioblastoma treatment[J]. Nature Communications, 2023, 14(1): 4557.
[2] Yao S, Yin J, Liu W, et al. A novel Gboxin analog induces OXPHOS inhibition and mitochondrial dysfunction-mediated apoptosis in diffuse large B-cell lymphoma[J]. Bioorganic Chemistry, 2022, 127: 106019.
[3] Jiao X, Yu X, Gong C, et al. Erythrocyte-cancer hybrid membrane-camouflaged mesoporous silica nanoparticles loaded with gboxin for glioma-targeting therapy[J]. Current Pharmaceutical Biotechnology, 2022, 23(6): 835-846.
[4] Crunkhorn S. Targeting cancer cell metabolism in glioblastoma[J]. Nature Reviews Cancer, 2019, 19(5): 250-250.
[5] Shi Y, Lim S K, Liang Q, et al. Gboxin is an oxidative phosphorylation inhibitor that targets glioblastoma[J]. Nature, 2019, 567(7748): 341-346.
Gboxin是癌细胞中氧化磷酸化(OXPHOS)的抑制剂,能够靶向抑制胶质母细胞瘤(GBM)[1]。Gboxin是一种含有正电荷的三取代苯并咪唑鎓化合物,可特异性抑制多种癌细胞系的生长[2]。Gboxin通过抑制F0F1 ATP酶复合物V的活性来特异性抑制GBM生长,然而其抗GBM作用受到血液循环不良、血脑屏障(BBB)和非特异性GBM组织/细胞摄取的严重限制[3]。Gboxin能够抑制硫氧还蛋白相互作用蛋白的表达,硫氧还蛋白相互作用蛋白是葡萄糖摄取和消耗的调节剂,也是氧化磷酸化OXPHOS的靶标[4]。
在体外,Gboxin(0-15μM)处理HTS细胞、原代MEF细胞和星形胶质细胞96h,显著抑制了HTS细胞的生长,但不抑制原代MEF和星形胶质细胞的生长,降低了HTS细胞中线粒体膜电位[5]。
Cell experiment [1]: | |
Cell lines |
HTS cells、primary MEFs、astrocytes |
Preparation Method |
HTS cells, MEFs, and astrocytes were exposed to increasing doses(0, 185, 555, 1667, 5000, 15000nM) of Gboxin for 96h, followed by cell viability assays. |
Reaction Conditions |
0, 185, 555, 1667, 5000, 15000nM; 96h |
Applications |
Gboxin specifically inhibit the growth of HTS cells but not that of cycling primary MEFs or astrocytes. |
References: |
Cas No. | 2101315-36-8 | SDF | |
Canonical SMILES | O=C(O[C@H]1[C@H](C(C)C)CC[C@@H](C)C1)CN2C(CC)=[N+](C)C3=CC=CC=C23.[Cl-] | ||
分子式 | C22H33ClN2O2 | 分子量 | 392.96 |
溶解度 | DMSO : 32.5 mg/mL (82.71 mM) | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.5448 mL | 12.7239 mL | 25.4479 mL |
5 mM | 0.509 mL | 2.5448 mL | 5.0896 mL |
10 mM | 0.2545 mL | 1.2724 mL | 2.5448 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet